|
Profile
|
Delegates :
Masanobu Sugawara |
|
Incorporated :
October 13 , 2010 |
Paid in Capital :
10 Million yen A group company of KANEKA |
Employees :
14 人 |
Address :
SHARP KASHIWA Building 4F 273-1, Kashiwa, Kashiwa-shi CHIBA
〒277-0005
|
TEL/FAX :
+81-4-7137-6301 / +81-4-7132-7530 |
URL:
https://www.genefrontier.com/en/?noredirect=en_US |
Attachment :
|
Mission/Background :
GeneFrontier Corporation (GFC) is a Japanese biotech company, which is one of the group companies of KANEKA Corporation. GFC is focusing on biopharmaceutical R&D support business with innovative products and services especially in protein based biologics including antibody/peptide. Also, GFC is looking at next era of antibody therapeutics in Biologics. GFC is developing its own new technology for antibody therapeutics and beyond antibodies, like scaffold/peptide. |
Technology & Business
|
GeneFrontier is providing unique screening technology based on ribosome display. It enables to screen highly diversified libraries in simpler and faster way comparing to the conventional methods such as phage display. On the other hand, we are developing our own antibody therapeutic programs for inflammatory diseases and oncology. We are looking for the opportunity for licensing out to pharmaceutical company for further development.
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
PUREfrexRD
|
Service/Marketing
|
Screening method based on ribosome display for R&D of protein/peptide based biologics.
|
Alliance with pharmaceutical companies based on PUREfrexRD.
|
Therapeutic antibody: GFC101
|
Preclinical
|
Fully human antibody for inflammatory diseases such as asthma, COPD, colitis and RA.
|
Licensing out to pharmaceutical company.
|
Therapeutic antibody: GFC201
|
Preclinical
|
Fully human antibody for oncology, especially for NSCLC and Breast cancer.
|
Licensing out to pharmaceutical company.
|
Therapeutic antibody: GFC301
|
Discovery
|
Fully human antibody for arthritis(OA and RA). For combination therapy with existing biologics for RA.
|
Licensing out to pharmaceutical company.
|
|
|
|
|
Highlights
|
We achieved three deals based on PUREfrexRD since 2013.
|
Hot news
|
We received governmental grant through AMED for further development of GFC201.
|
Alliance strategy
|
We are looking for the partner for technology transfer or collaboration based on PUREfrexRD. Also, we are looking for the partner for licensing out for our therapeutic antibody pipelines.
|
|
|